A mixture containing galactooligosaccharide, produced by the enzymic activity of Bifidobacterium bifidum, reduces Salmonella enterica serovar Typhimurium infection in mice

• Published in: Journal of medical microbiology Vol. 58; no. 1; pp. 37 - 48
• Main Authors: Searle, Laura E. J, Best, Angus, Nunez, Alejandro, Salguero, Francisco J, Johnson, Linda, Weyer, Ute, Dugdale, Alexandra H, Cooley, William A, Carter, Ben, Jones, Gareth, Tzortzis, George, Woodward, Martin J, La Ragione, Roberto M
• Format: Journal Article
• Language: English
• Published: Reading Soc General Microbiol 01.01.2009; Society for General Microbiology
• Subjects: Animals; Bacterial diseases; Bacterial diseases of the digestive system and abdomen; Bacteriology; Bifidobacterium - enzymology; Biological and medical sciences; Feces - microbiology; Female; Fundamental and applied biological sciences. Psychology; HT29 Cells; Human bacterial diseases; Humans; Ileum - microbiology; Ileum - pathology; Ileum - ultrastructure; Infectious diseases; Liver - microbiology; Medical sciences; Mice; Microbiology; Miscellaneous; Oligosaccharides - therapeutic use; Salmonella Infections - drug therapy; Salmonella Infections - microbiology; Salmonella typhimurium - drug effects; Spleen - microbiology; Lactic acid bacteria; Actinomycetaceae; Microbiology; Rodentia; Salmonella typhimurium; Actinomycetales; Infection; Vertebrata; Mammalia; Mouse; Bacteriosis; Bacteria; Actinomycetes; Salmonellosis; Bifidobacterium bifidum; Enterobacteriaceae
• ISSN: 0022-2615; 1473-5644
• DOI: 10.1099/jmm.0.004390-0

1 Veterinary Laboratories Agency (VLA), Weybridge, Woodham Lane, New Haw, Addlestone, Surrey KT15 3NB, UK 2 Faculty of Veterinary Science, University of Liverpool, Leahurst, Chester High Road, Neston, Wirral CH64 7TE, UK 3 South East Wales Trials Unit, School of Medicine, Cardiff University, Cardiff CF14 4XN, UK 4 Clasado Ltd, 5 Canon Harnett Court, Wolverton Mill, Milton Keynes MK12 5NF, UK Correspondence Laura E. J. Searle l.searle{at}vla.defra.gsi.gov.uk Received June 23, 2008 Accepted September 22, 2008 The prebiotic Bimuno ® is a mixture containing galactooligosaccharide, produced by the galactosyltransferase activity of Bifidobacterium bifidum NCIMB 41171 in the presence of lactose. Previous studies have implicated prebiotics in reducing infections by enteric pathogens, thus it was hypothesized that Bimuno ® may confer some protection in the murine host from Salmonella enterica serovar Typhimurium ( S. Typhimurium) infection. In this study, infection caused by S. Typhimurium SL1344nal r in the presence or absence of Bimuno ® was assessed using tissue culture assays, a murine ligated ileal gut loop model and a murine oral challenge model. In tissue culture adherence and invasion assays with HT-29-16E cells, the presence of 2 mM Bimuno ® significantly reduced the invasion of S. Typhimurium SL1344nal r ( P <0.0001). In the murine ligated ileal gut loops, the presence of Bimuno ® prevented colonization and the associated pathology of S. Typhimurium. In the BALB/c mouse model, the oral delivery of Bimuno ® prior to challenge with S. Typhimurium resulted in significant reductions in colonization in the five organs sampled, with highly significant reductions being observed in the spleen at 72 and 96 h post-challenge ( P =0.0002, <0.0001, respectively). Collectively, the results indicate that Bimuno ® significantly reduced the colonization and pathology associated with S. Typhimurium infection in a murine model system, possibly by reducing the invasion of the pathogen into host cells. Abbreviations: GOS, galactooligosaccharide; HE, haematoxylin and eosin; VLA, Veterinary Laboratories Agency.